Insider · CIK 0001423327
Rohan Palekar
ceoofficerdirector
Files at NGNE (Neurogene Inc.), ETNB (89bio, Inc.). First filing Nov 25, 2024, latest Dec 10, 2024.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
2 / 0
$123k bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 44Moderate | 89bio, Inc. | $39k 5,000 shares | +1% | - | |
| 42Moderate | 89bio, Inc. | $84k 10,000 shares | +2% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Feb 20, 2026 | NGNE Neurogene Inc. | AGrant or award Non-Qualified Stock Option (right to buy)derivative | +12,050 | $0.00 | $0 | 12,050 | Feb 24, 2026 |
| Oct 30, 2025 | ETNB 89bio, Inc. | AGrant or award Common Stock | +125,000 | $0.00 | $0 | 934,273 | Oct 30, 2025 |
| Oct 30, 2025 | ETNB 89bio, Inc. | UTender of shares Common Stock | -934,273 | - | - | 0 | Oct 30, 2025 |
| Oct 30, 2025 | ETNB 89bio, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -120,231 | $0.00 | $0 | 0 | Oct 30, 2025 |
| Oct 30, 2025 | ETNB 89bio, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -132,242 | $0.00 | $0 | 0 | Oct 30, 2025 |
| Oct 30, 2025 | ETNB 89bio, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -170,000 | $0.00 | $0 | 0 | Oct 30, 2025 |
| Oct 30, 2025 | ETNB 89bio, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -203,750 | $0.00 | $0 | 0 | Oct 30, 2025 |
| Oct 30, 2025 | ETNB 89bio, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -220,000 | $0.00 | $0 | 0 | Oct 30, 2025 |
| Oct 30, 2025 | ETNB 89bio, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -300,000 | $0.00 | $0 | 0 | Oct 30, 2025 |
| Oct 30, 2025 | ETNB 89bio, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -605,000 | $0.00 | $0 | 0 | Oct 30, 2025 |
| Oct 30, 2025 | ETNB 89bio, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -848,000 | $0.00 | $0 | 0 | Oct 30, 2025 |
| Aug 1, 2025 | ETNB 89bio, Inc. | FTax withholding Common Stock | -55,836 | $9.16 | $511k | 808,070 | Aug 5, 2025 |
| Jun 12, 2025 | NGNE Neurogene Inc. | AGrant or award Non-Qualified Stock Option (right to buy)derivative | +12,050 | $0.00 | $0 | 12,050 | Jun 13, 2025 |
| Feb 17, 2025 | ETNB 89bio, Inc. | FTax withholding Common Stock | -3,249 | $10.57 | $34k | 862,240 | Feb 19, 2025 |
| Feb 9, 2025 | ETNB 89bio, Inc. | FTax withholding Common Stock | -8,946 | $11.41 | $102k | 864,692 | Feb 11, 2025 |
| Feb 1, 2025 | ETNB 89bio, Inc. | AGrant or award Common Stock | +212,000 | $0.00 | $0 | 683,236 | Feb 4, 2025 |
| Feb 1, 2025 | ETNB 89bio, Inc. | AGrant or award Common Stock | +200,000 | $0.00 | $0 | 883,236 | Feb 4, 2025 |
| Feb 1, 2025 | ETNB 89bio, Inc. | FTax withholding Common Stock | -9,598 | $9.60 | $92k | 873,638 | Feb 4, 2025 |
| Feb 1, 2025 | ETNB 89bio, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +848,000 | $0.00 | $0 | 848,000 | Feb 4, 2025 |
| Dec 6, 2024 | ETNB 89bio, Inc. | POpen-market purchase Common Stock | +5,000 | $7.89 | $39k | 471,236 | Dec 10, 2024 |
| Nov 22, 2024 | ETNB 89bio, Inc. | POpen-market purchase Common Stock | +10,000 | $8.35 | $84k | 466,236 | Nov 25, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.